Contact us
Aromatase inhibitors (AIs) are used sequentially to treat ER+ breast cancer, yet resistance limits benefit.
This session integrates WES from 11 patients across three treatment timepoints (Neoletexe trial) with single-cell DNA sequencing validation to reconstruct subclonal architectures.
We’ll connect rising cancer cell fraction trajectories with reduced response, contrast exemestane- vs. letrozole-resistant clones, and highlight clinically actionable alterations—spanning PI3K/AKT/mTOR,
CDK4/6, DNA repair, and immune checkpoint pathways.
Speaker:
Dr Steven Chan
Associate Professor - Princess Margaret Cancer Centre; Senior Scientist, & Staff Physician - Department of Medicine at the University of Toronto
Dr. Chan is a senior scientist and staff physician at Princess Margaret Cancer Centre in Toronto. He is also an Associate Professor in the Department of Medicine at the University of Toronto. He received his medical and research training at Stanford University
in California where he earned his M.D. and Ph.D. degree in Immunology. He completed his internal medicine residency and adult hematology fellowship at Stanford Hospital and Clinics. He started his independent research program at Princess Margaret Cancer Centre
in 2015. His current research focuses on developing novel therapeutic approaches against acute myeloid leukemia and clonal hematopoiesis.
